LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (Amex: BPA) will be hosting a conference call at 8:45 a.m. ET to provide an update on U.S. Food and Drug Administration requirements for the development of LibiGel in the treatment of female sexual dysfunction and BioSante’s LibiGel clinical development activities.
